Linkage is now part of Thermo Fisher's transplant diagnostics business, One Lambda. Linkage's flagship product line is its real-time PCR technology, LinkSeq.
The company also said it has closed a new $25 million debt facility, and will use the proceeds to retire outstanding debt and bolster the launch of AlloSure.
The algorithm identifies proteins in blood samples taken after bone marrow transplants that predict patients at risk for severe graft-versus-host disease.
The firm missed analyst estimates for revenues and loss per share, citing a continued investment in its AlloSure NGS test for the wider-than-expected loss.
An analysis of samples taken a year after kidney transplant identified overlapping gene expression signatures associated with acute and chronic rejection.
Yale Environment 360 writes that synthetic and conservation biologists aren't always on the same wavelength, but they are trying to reach an understanding.
